UNASSIGNED: A cross-sectional study was done from June 2019 to March 2020 to describe the genetic diversity and drug-resistance profiles of MTBC isolates. Sputum specimens were collected and cultured in the Löwenstein-Jensen culture medium. Line Probe Assay, MTBDRplus VER 2.0, and MTBDRsl VER 2.0 were used to detect first-and second-line anti-TB drug-resistance patterns. A spoligotyping technique was utilized to characterize the genetic diversity. Statistical analysis was performed using STATA 15.
UNASSIGNED: Of 560 PTB-symptomatic participants, 122 (21.8%) were culture-positive cases. Spoligotyping of 116 isolates revealed diverse MTBC sublineages, with four major lineages: Euro-American (EA) (Lineage 4), East-African-Indian (EAI) (Lineage 3), Ethiopian (ETH) (Lineage 7), East Asian (EA) (Lineage 2). The majority (96.6%) of the isolates were EA (lineage 4) and EAI, with proportions of 54.3% and 42.2%, respectively. A total of 31 spoligotype patterns were identified, 26 of which were documented in the SITVIT2 database. Of these, there were 15 unique spoligotypes, while eleven were grouped with 2-17 isolates. SIT149/T3-ETH (n = 17), SIT26/CAS1-DELHI (n = 16), SIT25/CAS1-DELHI (n = 12), and SIT52/T2 (n = 11) spoligotypes were predominant. A rare spoligotype pattern: SIT41/Turkey and SIT1/Beijing, has also been identified in North Shewa. The overall clustering rate of sub-lineages with known SIT was 76.4%.Of the 122 culture-positive isolates tested, 16.4% were resistant to rifampicin (RIF) and/or isoniazid (INH). Multidrug-resistant TB (MDR-TB) was detected in 12.3% of isolates, five of which were fluoroquinolones (FLQs) resistant. SIT149/T3-ETH and SIT21/CAS1-KILI sublineages showed a higher proportion of drug resistance.
UNASSIGNED: Diverse MTBC spoligotypes were identified, with the T and CAS families and EA (lineage 4) predominating. A high prevalence of drug-resistant TB, with SIT149/T3-ETH and CAS1-KILI sublineages comprising a greater share, was observed. A study with large sample size and a sequencing method with stronger discriminatory power is warranted to understand better the genetic diversity of circulating MTBC in this cohort of study, which would help to adopt targeted interventions.
■从2019年6月至2020年3月进行了一项横断面研究,以描述MTBC分离株的遗传多样性和耐药性。收集痰标本并在Löwenstein-Jensen培养基中培养。线探针测定,MTBDRplusVER2.0和MTBDRslVER2.0用于检测一线和二线抗TB药物抗性模式。利用spoligotyping技术来表征遗传多样性。使用STATA15进行统计分析。
■在560名有PTB症状的参与者中,122例(21.8%)为培养阳性病例。116个分离株的Spoligotyping揭示了不同的MTBC亚谱系,有四个主要谱系:欧美(EA)(谱系4),东非印第安人(EAI)(谱系3),埃塞俄比亚(ETH)(谱系7),东亚(EA)(谱系2)。大多数(96.6%)的分离株是EA(谱系4)和EAI,比例分别为54.3%和42.2%,分别。总共确定了31种spoligotype模式,其中26个记录在SITVIT2数据库中。其中,有15种独特的spoligotypes,而11个被分组为2-17个分离株。SIT149/T3-ETH(n=17),SIT26/CAS1-DELHI(n=16),SIT25/CAS1-DELHI(n=12),以SIT52/T2(n=11)为主。一种罕见的spoligotype模式:SIT41/土耳其和SIT1/北京,在北谢瓦也被确认。具有已知SIT的子谱系的总体聚类率为76.4%。在测试的122株培养阳性菌株中,16.4%对利福平(RIF)和/或异烟肼(异烟肼)耐药。在12.3%的分离株中检测到耐多药结核病(MDR-TB),其中五种是氟喹诺酮类药物(FLQs)耐药。SIT149/T3-ETH和SIT21/CAS1-KILI亚谱系显示较高比例的耐药性。
■确定了不同的MTBCspoligotypes,以T和CAS家族和EA(谱系4)为主。耐药结核病的高流行率,SIT149/T3-ETH和CAS1-KILI子谱系占更大份额,被观察到。在本研究队列中,有必要进行大样本量和具有更强鉴别力的测序方法的研究,以更好地了解循环MTBC的遗传多样性。这将有助于采取有针对性的干预措施。